A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

2023-505127-31-00 Protocol IGM-2323-102 Human pharmacology (Phase I) - Other Ended

Start 8 Feb 2024 · End 11 Feb 2025 · Status Ended · 1 EU/EEA countries · 7 sites · Protocol IGM-2323-102

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 29
Countries 1
Sites 7

Rheumatoid Arthritis

Key facts

Sponsor
IGM Biosciences Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
8 Feb 2024 → 11 Feb 2025
Decision date (initial)
2023-11-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Rheumatoid Arthritis

VersionLevelCodeTermSystem organ class
21.0 PT 10039073 Rheumatoid arthritis 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

IGM Biosciences Inc.

Sponsor organisation
IGM Biosciences Inc.
Address
325 East Middlefield Road
City
Mountain View
Postcode
94043-4003
Country
United States

Scientific contact point

Organisation
IGM Biosciences Inc.
Contact name
Rebecca Kunder

Public contact point

Organisation
IGM Biosciences Inc.
Contact name
Rebecca Kunder

Locations

1 EU/EEA country · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Poland Ended 9 7
Rest of world
United States
20

Investigational sites

Poland

7 sites · Ended
Nova Reuma Domyslawska I Rusilowicz Lekarza Reumatologa I Fizjoterapeuty sp.p.
NA, Ul Prowiantowa 15/4, 15-707, Bialystok
Med Polonia Sp. z o.o.
NA, Obornicka 262, 60-693, Poznan
Medyczne Centrum Hetmanska Piotr Leszczyński
NA, ul. Hetmańska 55/1, 60-218, Poznań
Medicover Integrated Clinical Services Sp. z o.o.
NA, Ul. Jana Karola Chodkiewicza 19c, 85-065, Bydgoszcz
NZOZ Lecznica Mak Med s.c.
NA, Ul. Wisniowa 22, 05-830, Nadarzyn
Reumedika sp. z o.o
NA, Wejcherowska 16, 60-446, Poznań
Prywatna Praktyka Lekarska Prof. Dr HabMed Pawel Hrycaj
NA, os. Rzeczpospolitej 6/202, 61-397, Poznan

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Poland 2024-02-08 2024-05-06 2025-01-09

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-08-11 Poland Acceptable
2023-11-27
2023-11-30
2 SUBSTANTIAL MODIFICATION SM-1 2023-12-21 Poland Acceptable
2024-02-12
2024-03-04
3 SUBSTANTIAL MODIFICATION SM-2 2024-09-06 Poland Acceptable
2024-10-21
2024-10-28